180 related articles for article (PubMed ID: 11225746)
1. Impact of insulin lispro on HbA1c values in insulin pump users.
Garg SK; Anderson JH; Gerard LA; Mackenzie TA; Gottlieb PA; Jennings MK; Chase HP
Diabetes Obes Metab; 2000 Oct; 2(5):307-11. PubMed ID: 11225746
[TBL] [Abstract][Full Text] [Related]
2. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
[TBL] [Abstract][Full Text] [Related]
3. Use of insulin lispro in continuous subcutaneous insulin infusion treatment. Results of a multicenter trial. German Humalog-CSII Study Group.
Renner R; Pfützner A; Trautmann M; Harzer O; Sauter K; Landgraf R
Diabetes Care; 1999 May; 22(5):784-8. PubMed ID: 10332682
[TBL] [Abstract][Full Text] [Related]
4. Improvement of HbA1c and blood glucose stability in IDDM patients treated with lispro insulin analog in external pumps.
Melki V; Renard E; Lassmann-Vague V; Boivin S; Guerci B; Hanaire-Broutin H; Bringer J; Belicar P; Jeandidier N; Meyer L; Blin P; Augendre-Ferrante B; Tauber JP
Diabetes Care; 1998 Jun; 21(6):977-82. PubMed ID: 9614617
[TBL] [Abstract][Full Text] [Related]
5. Comparison of human regular and lispro insulins after interruption of continuous subcutaneous insulin infusion and in the treatment of acutely decompensated IDDM.
Attia N; Jones TW; Holcombe J; Tamborlane WV
Diabetes Care; 1998 May; 21(5):817-21. PubMed ID: 9589247
[TBL] [Abstract][Full Text] [Related]
6. Human insulin analogue [LYS(B28), PRO(B29)]: the ideal pump insulin?
Schmauss S; König A; Landgraf R
Diabet Med; 1998 Mar; 15(3):247-9. PubMed ID: 9545126
[TBL] [Abstract][Full Text] [Related]
7. A comparison of insulin lispro and buffered regular human insulin administered via continuous subcutaneous insulin infusion pump.
Raskin P; Holcombe JH; Tamborlane WV; Malone JI; Strowig S; Ahern JA; Lavent F
J Diabetes Complications; 2001; 15(6):295-300. PubMed ID: 11711322
[TBL] [Abstract][Full Text] [Related]
8. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.
Pfützner A; Küstner E; Forst T; Schulze-Schleppinghoff B; Trautmann ME; Haslbeck M; Schatz H; Beyer J
Exp Clin Endocrinol Diabetes; 1996; 104(1):25-30. PubMed ID: 8750567
[TBL] [Abstract][Full Text] [Related]
9. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime.
Ciofetta M; Lalli C; Del Sindaco P; Torlone E; Pampanelli S; Mauro L; Chiara DL; Brunetti P; Bolli GB
Diabetes Care; 1999 May; 22(5):795-800. PubMed ID: 10332684
[TBL] [Abstract][Full Text] [Related]
10. Effect of the fast-acting insulin analog lispro on the risk of nocturnal hypoglycemia during intensified insulin therapy. U.K. Lispro Study Group.
Heller SR; Amiel SA; Mansell P
Diabetes Care; 1999 Oct; 22(10):1607-11. PubMed ID: 10526722
[TBL] [Abstract][Full Text] [Related]
11. Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetes.
Bode B; Weinstein R; Bell D; McGill J; Nadeau D; Raskin P; Davidson J; Henry R; Huang WC; Reinhardt RR
Diabetes Care; 2002 Mar; 25(3):439-44. PubMed ID: 11874927
[TBL] [Abstract][Full Text] [Related]
12. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime.
Lalli C; Ciofetta M; Del Sindaco P; Torlone E; Pampanelli S; Compagnucci P; Cartechini MG; Bartocci L; Brunetti P; Bolli GB
Diabetes Care; 1999 Mar; 22(3):468-77. PubMed ID: 10097931
[TBL] [Abstract][Full Text] [Related]
13. Italian multicentre study of intensive therapy with insulin lispro in 1184 patients with Type 1 diabetes.
Valle D; Santoro D; Bates P; Scarpa L;
Diabetes Nutr Metab; 2001 Jun; 14(3):126-32. PubMed ID: 11476359
[TBL] [Abstract][Full Text] [Related]
14. Lispro insulin treatment in comparison with regular human insulin in type 2 diabetic patients living in nursing homes.
Velussi M
Diabetes Nutr Metab; 2002 Apr; 15(2):96-100. PubMed ID: 12059098
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
Vignati L; Anderson JH; Iversen PW
Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449
[TBL] [Abstract][Full Text] [Related]
16. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus.
Wilde MI; McTavish D
Drugs; 1997 Oct; 54(4):597-614. PubMed ID: 9339963
[TBL] [Abstract][Full Text] [Related]
17. Strategies toward improved control during insulin lispro therapy in IDDM. Importance of basal insulin.
Ebeling P; Jansson PA; Smith U; Lalli C; Bolli GB; Koivisto VA
Diabetes Care; 1997 Aug; 20(8):1287-9. PubMed ID: 9250455
[TBL] [Abstract][Full Text] [Related]
18. The effect of the insulin analog lispro on nighttime blood glucose control in type 1 diabetic patients.
Ahmed AB; Home PD
Diabetes Care; 1998 Jan; 21(1):32-7. PubMed ID: 9538967
[TBL] [Abstract][Full Text] [Related]
19. [How should we use the short-acting insulin analog Lys-Pro in external continuous subcutaneous pumps?].
Guerci B; Jeandidier N; Lassmann-Vague V; Renard E; Hanaire-Broutin H
Diabetes Metab; 2000 Dec; 26(6):513-9. PubMed ID: 11173725
[TBL] [Abstract][Full Text] [Related]
20. Insulin lispro in CSII: results of a double-blind crossover study.
Zinman B; Tildesley H; Chiasson JL; Tsui E; Strack T
Diabetes; 1997 Mar; 46(3):440-3. PubMed ID: 9032100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
